GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [PSA] Zepbound is not what most of this community thinks it is — 63 comments in the full submission. View in context.
2.5k
c/tirzepatide·submitted 4 months ago by u/rania_marchand

[PSA] Zepbound is not what most of this community thinks it is

Discussionbranch of 8 comments

Putting this at the top of the board where it belongs: Zepbound is not what most of this community thinks it is. The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to. Vials and pens carry the same…

Read the full submission and all 63 comments →

This branch

8 comments, started 4 months ago
u/gustav_vermeulen273 points·4 months ago

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

replysharereportpermalink
u/rania_marchand0 points·4 months ago

switching from sema is not a dose conversion, there is no clean equivalence

replysharereportpermalink
u/blunt_coldbox291 point·4 months ago

Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.

replysharereportpermalink
u/aksel_kjaer1 point·4 months ago

30kg over 69 weeks, never went past 10mg, and fatigue stayed mild the whole way. Posting because the loud threads are all 15mg.

replysharereportpermalink
u/elin_varga2 points·4 months ago

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

replysharereportpermalink
u/ahmed_fonseca1 point·4 months ago

pens and vials are the same molecule, the price is the difference

replysharereportpermalink
u/copay_card_cc1 point·4 months ago

SURMOUNT-1 landed around 21% at 72 weeks on the top arm

replysharereportpermalink
u/piotr_nascimento120 points·4 months ago·edited

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

replysharereportpermalink

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.